CaroGen is developing a pipeline of innovative and transformative immunotherapies for various diseases of high unmet need

  • Chronic Hepatitis B Viral Infection (CHB) in collaboration with Yale School of Medicine and Albany Medical College
  • Colon Cancer Immunotherapy in collaboration with researchers at the University of Connecticut
  • Clostridium difficile, a bacterial infection
Pipeline of innovative and transformative immunotherapies


Worldwide, approximately 240 million people live with CHB and 600,000 die each year from HBV-associated liver disease and cancer. The hepatitis B program is CaroGen's lead program and has completed initial proof-of-concept testing in animals which was published in August 2015 in the Journal of Virology. The HBV program has selected a clinical candidate capable of stimulating the immune system to multiple HBV target antigens.

Colorectal Cancer (CRC)

It is the second leading cause of cancer-related deaths in the United States. CRC was estimated to have caused over 49,000 deaths in 2016. CaroGen has embarked on a collaborative effort on CRC with prominent scientists from UConn Health. Proteins have been selected for VLV-based delivery and are undergoing lead optimization.

Clostridium difficile

It is a microbial infection that causes severe diarrhea and is a CDC urgent threat due to antimicrobial resistance. It is currently estimated that there are 500,000 infections per year in the US resulting 29,000 deaths/year. There are currently no vaccines for either the prevention or treatment of C. difficile and limited antimicrobial drugs available to treat established infections. CaroGen has initiated investigations to identify the proteins that are the best targets for treatment and/or prevention of C. difficile.